Alembic Pharmaceuticals rises on getting USFDA`s final nod for Levothyroxine Sodium Tablets
Alembic Pharmaceuticals is currently trading at Rs. 755.85, up by 8.20 points or 1.10% from its previous closing of Rs. 747.65 on the BSE.
The scrip opened at Rs. 747.70 and has touched a high and low of Rs. 760.10 and Rs. 745.95 respectively. So far 4804 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1107.80 on 30-Jun-2025 and a 52 week low of Rs. 635.30 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 836.00 and Rs. 711.00 respectively. The current market cap of the company is Rs. 14807.10 crore.
The promoters holding in the company stood at 69.74%, while Institutions and Non-Institutions held 20.43% and 9.83% respectively.
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Synthroid Tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg, of AbbVie, Inc. (AbbVie).
Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Levothyroxine Sodium Tablets USP have an estimated market size of $1,869 million for twelve months ending March 2026 according to IQVIA. The company has a cumulative total of 239 ANDA approvals (220 final approvals and 19 tentative approvals) from USFDA.
